Soluble programmed cell death-1 is increased in axial spondyloarthritis and present at the local site of pathology | Synapse
January 25, 2026
Soluble programmed cell death-1 is increased in axial spondyloarthritis and present at the local site of pathology
Key Points
The study aims to investigate the role of the PD-1 pathway in axial spondyloarthritis (axSpA) pathology.
Assessment of soluble programmed cell death-1 (sPD-1) levels in patients with axSpA
Evaluation of immune activation within inflamed tissue
Analysis of the microenvironment surrounding the affected areas
Increased levels of sPD-1 observed in patients with axSpA
Presence of sPD-1 noted at tissue sites of inflammation
Suggests persistent low-level immune activation in the disease process
Abstract
We suggest a dual role for the PD-1 pathway in the pathogenesis of axSpA, acting in the inflamed microenvironment, with sPD-1 being suggestive of continued low immune activation.